Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)

NCT04698681 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.

NCT NCT04698681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04698681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Lead sponsor
Calithera Biosciences, Inc
Phase
Observational
Overall status
Terminated
Start date
January 19, 2021
Completion date
February 9, 2022
Enrollment
20 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

keap1 gene mutation, nfe2l2 gene mutation, non-small cell lung cancer, non-squamous non-small cell neoplasm of lung, non-squamous non-small-cell lung cancer, nrf2 mutation